Posters

      An Exploratory Inhalation Toxicity Study with Cigarette Mainstream Smoke in Two Transgenic Mouse Strains, rasH2 and p53+/-

      Vanscheeuwijck, P.; Meurrens, K.; Arts, J.; Duistermaat, E.; Muijser, H.; Kuper, F.; Terpstra, P.
      Conference date
      Sep 20, 2006
      Conference name
      Eurotox 2006
      Link to more information
      Link to more information
      Topic
      Summary

      Two mouse models for carcinogenicity testing proposed by the ILSI/HESI program were exposed to cigarette mainstream smoke (MS): the transgenic mouse expressing the human c-Ha-ras proto-oncogene (rasH2) and the heterozygous tumor suppressor p53 knock-out mouse (p53). Female mice (16/group) were exposed to air (SHAM) or MS from the reference cigarette 2R4F for 6 months (3 h/d [low] or 6 h/d [high], 5 d/wk) at a concentration of 240 µg total particulate matter/l. Satellite groups (8-16/group) were kept for 3 months post-exposure. Additional groups of 6 mice were initiated by i.p. administration of urethane (250 mg/kg) before exposure. Body weight gain and lung nodule incidence and multiplicity were assessed as endpoints. Lungs were made transparent (Tellyesniczky fixative) for macroscopic evaluation and a limited number of sections were taken for histopathological analysis of the nodules. Body weight gain of MS-exposed mice was reduced in rasH2 mice only (10%; end of exposure period). There were no statistically significant MS-mediated increases in the incidence and multiplicity of lung nodules in either strain. Incidence is given for sham, low dose and high dose groups, respectively. At the end of the exposure period incidence was 3/16, 3/16 and 5/16 in rasH2 mice and 2/16, 0/16, and 5/16 in p53 mice. At the end of the post-exposure period incidence was 2/15, ─ and 3/16 in rasH2 mice and 5/16, 1/8 and 2/16 in p53 mice. Treatment with urethane resulted in a high nodule incidence with no statistically significant differences vs sham for both mouse strains. In rasH2 mice incidence was 5/6, 6/6 and 3/6 at the end of the exposure period and 6/6, ─ and 4/6 at the end of the post-exposure period. In p53 mice incidence was 0/6, 3/6 and 0/6 at the end of the exposure period and 2/6, 3/8 and 0/6 at the end of the post-exposure period. Histopathological evaluation showed the presence of bronchiolar-alveolar adenomas and carcinomas in rasH2 mice only, irrespective of urethane injection. Under the conditions of this study, the mouse models for carcinogenicity testing, rasH2 and p53, were not suitable for detecting MS-induced lung tumors. 

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.